Literature DB >> 7495117

Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.

A Reissigl1, J Pointner, W Horninger, O Ennemoser, H Strasser, H Klocker, G Bartsch.   

Abstract

OBJECTIVES: This study was designed to compare the usefulness of the normal prostate-specific antigen (PSA) level and the age-referenced PSA level in a large screening study for early detection of prostate cancer.
METHODS: A total of 21,078 subjects (aged 45 to 75 years) were participants in a 1-year prostate cancer screening project with PSA as the initial test. Of the volunteers, 1618 (8%) showed an elevated PSA level according to age-specific reference ranges, and using the normal PSA cutoff point (4.0 ng/mL), 1872 (9%) had elevated PSA levels between 4.0 and 6.5 ng/mL.
RESULTS: Biopsies in both groups were performed if the PSA level was elevated. We evaluated the effect on biopsy rate and cancer detection. A PSA cutoff point of 2.5 ng/mL in men 45 to 49 years old and a PSA cutoff point of 3.5 ng/mL in men 50 to 59 years old with normal digital rectal examination findings resulted in an 8% increase in the number of biopsies (66 of 778) and an 8% increase in organ-confined cancer detection. An increasing cutoff of 4.5 ng/mL in men 60 to 69 years old and 6.5 ng/mL in men 70 to 75 years old resulted in 21% fewer biopsies (205 of 983) and would have missed 4% of organ-confined tumors (8 of 220).
CONCLUSIONS: We conclude that the use of PSA age-specific reference ranges increases the detection of clinically important and organ-confined cancers in young men and decreases the number of biopsies in older men.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495117     DOI: 10.1016/S0090-4295(99)80297-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns.

Authors:  Nathan Lawrentschuk; Nikhil Daljeet; Clement Ma; Karen Hersey; Alexandre Zlotta; Neil Fleshner
Journal:  Int Urol Nephrol       Date:  2010-06-12       Impact factor: 2.370

2.  Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels.

Authors:  R M Hoffman; D L Clanon; B Littenberg; J J Frank; J C Peirce
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

3.  Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

Authors:  Danni L Meany; Lori J Sokoll; Daniel W Chan
Journal:  Expert Opin Med Diagn       Date:  2009-11-01

4.  Age-specific PSA reference ranges in Chinese men without prostate cancer.

Authors:  Zhi-Yong Liu; Ying-Hao Sun; Chuan-Liang Xu; Xu Gao; Luo-Man Zhang; Shan-Cheng Ren
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

Review 5.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

6.  Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.

Authors:  J Athene Lane; Joanne Howson; Jenny L Donovan; John R Goepel; Daniel J Dedman; Liz Down; Emma L Turner; David E Neal; Freddie C Hamdy
Journal:  BMJ       Date:  2007-11-15

Review 7.  The Role and Significance of Bioumoral Markers in Prostate Cancer.

Authors:  Traian Constantin; Diana Alexandra Savu; Ștefana Bucur; Gabriel Predoiu; Maria Magdalena Constantin; Viorel Jinga
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

8.  Screening for prostate cancer: updated experience from the Tyrol study.

Authors:  Wolfgang Horninger; Andreas Berger; Alexandre Pelzer; Helmut Klocker; Wilhelm Oberaigner; Dieter Schönitzer; Gianluca Severi; Chris Robertson; Peter Boyle; Georg Bartsch
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

Review 9.  Molecular diagnosis of prostate cancer.

Authors:  Eduardo I Canto; Shahrokh F Shariat; Kevin M Slawin
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.